CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 155 enrolled
Drug / intervention
TEMIRI +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02727387
NCT02727387Phase 2Completed

Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma

Italian Sarcoma Group·interventional·Posted Apr 4, 2016·Updated Sep 19, 2022

In Brief

A Phase 2 clinical trial evaluating TEMIRI, ADM, and 5 other interventions for Ewing's Sarcoma (ES). Completed, enrolled 155 participants across 13 sites.

Detailed Summary

Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy, radiotherapy and maintenance therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 4, 2016
Enrollment StartJun 1, 2009
Primary CompletionApr 29, 2022
TodayJul 2, 2026
Enrollment to primary: 12.9 yearsPosted 10.2 years ago

Interventions

TEMIRIdrug

Window therapy frontline for VHR patients

ADMdrug

Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide

IFOdrug

Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide

CYCdrug

Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide

ETOdrug

Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin

BUMELdrug

Consolidation phase

VINdrug

Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide